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ABSTRACT
Pharmacotherapy of acromegaly has been improved in recent years
as new long-acting somatostatin analogs have became available; they
have been suggested as an alternative treatment to pituitary surgery
and radiotherapy. To avoid the inconvenience of multiple daily in-
jections during long-term therapy, a slow release formulation of lan-
reotide (LAN), to be administered im at a dose of 30 mg every 7–14
days, has been introduced in the therapeutic management. The sup-
pressive effects of a short-term LAN treatment on GH and insulin-like
growth factor I (IGF-I) hypersecretion were shown to be similar to
those obtained with sc octreotide. However, scant data have been
reported concerning a long-term treatment with this drug. In the
present study the efficacy and tolerability of a 24-month LAN treat-
ment were evaluated in 118 active acromegalic patients; 71 had been
previously operated on and treated with sc octreotide (operated pa-
tients), 24 previously operated on had been irradiated and treated
with sc octreotide (irradiated patients), and the remaining 23 were
newly diagnosed (de novo patients). The efficacy was considered on
the basis of controlled GH (fasting, ,7.5 mU/L; glucose-suppressed,
,3.0 mU/L) and IGF-I (age-adjusted normal values) secretion. In the
118 patients as a whole, circulating GH and IGF-I levels were sig-
nificantly decreased during the 24-month LAN treatment (P , 0.0005
at all time points vs. basal value). After 24 months of therapy, con-
trolled GH and IGF-I levels were achieved in 64%, 37%, and 78% and
in 51%, 37%, and 70% of operated, irradiated, and de novo patients,
respectively. A reduction in tumor size was documented in 5 of 23 de
novo patients (22%). Among the 84 operated/irradiated with evident
tumor remnant, significant shrinkage was documented in 5 patients
(5.9%). Treatment was well tolerated by the majority of patients. Only
2 patients (1.7%) withdrew from LAN treatment due to severe side
effects.
In conclusion, a 24-month treatment with slow release lanreotide
(30 mg) is effective in reducing GH and IGF-I levels; furthermore, in
de novo patients it induces disease control in 70% of patients and
causes tumor shrinkage in 22% of them, with excellent compliance.
These data suggest that LAN can be used in long-term treatment of
acromegalic patients. (J Clin Endocrinol Metab 85: 4099–4103, 2000)
ACROMEGALY IS A rare disease, characterized by ex-cessive skeletal growth, soft tissue enlargement, and
high morbidity and mortality, mainly due to cardiovascular,
cerebrovascular, and respiratory abnormalities as well as to
metabolic alterations (1–9). Moreover, increased incidence of
benign and malignant tumors has been reported in acro-
megaly (2, 10–12), especially of colonic polyps and adeno-
carcinomas (10, 13–16). As the reduction of GH to “safe”
levels was reported to reduce the mortality rate (11), GH/
insulin-like growth factor I (IGF-I) hypersecretion needs to be
well controlled. The current approach involves surgery, ra-
diation, and pharmacological treatment with dopaminergic
drugs or somatostatin analogs, alone or in combination (17,
18–26). The therapeutic goal is to improve clinical symptoms
by suppressing GH and IGF-I hypersecretion, to achieve
disease control (27–29), and to reduce tumor mass to correct
or prevent local complication. Pharmacological treatment is
generally applied after unsuccessful surgery in the presence
of tumor remnant or invasiveness (30). Medical therapy us-
ing sc octreotide (OCT) two or three times a day has recently
been eclipsed by the introduction of new long-acting for-
mulation of somatostatin analogs, lanreotide (20–22, 31–37)
and octreotide-LAR (25, 38–40), that overcome the incon-
venience of multiple daily injections, which are unfavorable
for patients during long-term treatment.
Lanreotide (Ipsen Laboratories), a slow release (SR-) for-
mulation of the somatostatin analog BIM 23014, requiring an
im injection every 7–14 days, has become available in the last
few years in Italy. The effects of a short-term treatment with
SR-lanreotide (LAN) on GH and IGF-I hypersecretion were
similar to those obtained with octreotide (20–22, 31–35, 37),
whereas the results of chronic treatment have been poorly
investigated. In one study, LAN was reported to normalize
GH and IGF-I hypersecretion in 27.7% and 63.6% of 22 pa-
tients treated for 24/36 months (22).
The aim of the present study was to evaluate the effects of
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a 24-month LAN treatment in a large group of acromegalic
patients. The possibility that different therapeutic efficacy
was shown by LAN in de novo patients compared with those
previously treated with sc OCT was also investigated.
Subjects and Methods
Patients
One-hundred and eighteen patients with active acromegaly, 51 males
and 67 females, aged 49.4 6 15.4 yr (mean 6 sd; range, 20–82 yr; median,
50 yr), were included in this open study that was performed at the
Universities of Rome, Naples, and Turin (Italy). At study entry, acro-
megaly was clinically diagnosed on the basis of acral enlargement,
patient interview, and comparison of photographs taken during a 1- to
2-decade span to date the onset of acral enlargement. Biochemical di-
agnosis was carried out by assessing high plasma GH levels (75.9 6 8.1
mU/L), not suppressible below 3.0 mU/L after oral glucose tolerance
test (OGTT), elevated age-matched plasma IGF-I values (693.6 6 30.2
ng/mL). The OGTT was performed by measuring blood glucose and GH
every 30 min for 2 h after the oral administration of 75 g glucose. In 4
patients with overt diabetes, OGTT was not performed. Ninety-one
patients presented at diagnosis with microadenoma (mA), and 27 pre-
sented with macroadenoma (MA). In particular, 23 patients were newly
diagnosed (de novo patients), and 95 patients had been treated with sc
OCT before starting LAN treatment. Among these 95 unselected pa-
tients, 71 had also been previously operated on by the transsphenoidal
or transcranial route (operated patients), whereas 24 of them had re-
ceived conventional postoperative radiotherapy at least 1–5 yr before
entering the study (irradiated patients). The evidence of pituitary ade-
noma or remnant tissue was confirmed in 84 of the 95 OCT-pretreated
patients by magnetic resonance imaging (MRI) or computed tomogra-
phy (CT) scan. Eleven patients had secondary empty sella after surgery
and/or radiotherapy. The group of de novo patients included 15 women
(age, 51.4 6 4.9 yr; range, 22–77 yr; median, 50 yr) and 8 men (age, 45.1 6
4.5 yr; range, 29–65; median, 46 yr); 8 patients had mA, and 15 had MA,
with suprasellar and/or parasellar invasion in 12 patients. The most
common visual field defect, represented by bitemporal hemianopsia,
was present in 7 MA patients showing compression of the optic chiasm
at radiological imaging; moreover, 3 of 23 de novo patients presented
with growing headache. All patients gave their informed consent to the
study, which was approved by all local ethical committees.
Treatment protocol
At study entry, plasma IGF-I levels were assayed in duplicate from
a single sample, whereas the value of plasma GH was calculated as the
mean of a 2- to 6-h blood sampling (0800–1000 h or 0800–1400 h, with
30-min sampling). Ninety-five patients were treated with OCT (San-
dostatina, Novartis, Italy) at an initial dose of 0.15–0.30 mg/day, sc; this
dose was increased to achieve normal GH and IGF-I levels up to 0.6
mg/day. Before starting LAN treatment, all patients underwent a 30- to
60-day wash-out period. A general physical examination was carried out
before and every 3 months during treatment. All patients initially re-
ceived LAN every 14 days over a 3-month period. Thereafter, in 54
patients showing persistently high hormone levels, LAN was admin-
istered every 10 days. During treatment, the final GH level was calcu-
lated as the average value from at least 3 blood samples collected, at
15-min intervals, just before the next im injection of LAN. The disease
control after LAN treatment was considered when basal GH values were
less than 7.5 mU/L together with IGF-I values within the normal range
for age (27, 28). The time points of the study were defined as follows:
T0, pretreatment evaluation in 118 patients; T1, after 6 months of treat-
ment in 118 patients; T2, after 12 months of treatment in 114 patients; and
T3, after 24 months of treatment in 99 patients. As radiotherapy induces
hormone decrease over a prolonged time, GH and IGF-I levels were
measured after 1-month LAN withdrawal in the 24 irradiated patients.
All patients underwent gallbladder ultrasonography in the basal con-
dition and after 6, 12, and 24 months of treatment.
Hormonal assays
Plasma GH levels were measured by immunoradiometric assay
(HGH-CTK-IRMA Sorin, Saluggia, Italy). The sensitivity of the assay
was 0.6 mU/L; 1 mg/L corresponds to 3 mU/L (28). The intra- and
interassay coefficients of variation (CVs) were 4.5% and 7.9%, respec-
tively. Plasma IGF-I was determined by RIA after acid-ethanol extrac-
tion; intra- and interassay CVs were 3.4–5.4% and 5.9–7.1%, respec-
tively. In our laboratories, age-corrected normal ranges for IGF-I levels
were less than 483 ng/mL (20–30 yr), less than 397 ng/mL (31–40 yr),
less than 306 ng/mL (41–50 yr), and less than 249 ng/mL (.50 yr).
Radiological examination
A CT scan was carried out, before and after iv infusion of contrast
medium using a third generation scanner with 3.5-s acquisition times,
1.5-mm-thick axial and coronal sections, and scout-views. MRI (0.5–1.0
Tesla) was carried out with T1-weighted SE sequences and 3-mm slides
in coronal and sagittal sections before and after contrast enhancement
with gadolinium-DTPA. CT scan or MRI was carried out in the basal
condition and after 6, 12, and 24 months of LAN therapy. Significant
tumor shrinkage was defined as a greater than 20% decrease in the
pretreatment tumor volume calculated by the Di Chiro and Nelson
formula: volume 5 height 3 length 3 width 3 p/6 (41).
Statistical analysis
Unless otherwise specified, all data are presented as the mean 6 sem.
ANOVA, t test for unpaired data, Wilcoxon rank test, and x2 test were
used when appropriate; P , 0.05 was considered significant. Statistical
analysis was performed using StatView 5 software for Windows (SAS
Institute, Inc., Chicago, IL).
Results
Nadir levels of GH and IGF-I during previous OCT treat-
ment in the 95 patients were 19.2 6 2.4 mU/L and 378.7 6
18.3 ng/mL, respectively. In particular, controlled GH se-
cretion was achieved in 32 patients (33.7%), whereas normal
age-adjusted IGF-I levels were achieved in 45 patients
(74.4%). All patients received LAN at the dose of 30 mg every
14 days for the first 3 months. In 54 of 118 patients (45.8%),
the frequency of LAN injection was increased every 10 days,
resulting in disease control in 17% of patients. In the 118
patients as a whole, circulating GH and IGF-I levels were
significantly decreased during the 24 months of LAN treat-
ment (P , 0.0005 at all time points vs. basal time; Figs. 1 and
2). In particular at T0, plasma GH levels were lower in ir-
radiated patients (P , 0.05) than in those operated upon,
FIG. 1. Plasma GH levels (mean 6 SEM) in the group of acromegalic
patients (n 5 118) before and during long-term treatment with LAN.
*, P , 0.0005 vs. basal.
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whereas no difference in IGF-I levels was found in any group
(Table 1). After 6 months of LAN treatment, GH levels were
significantly lower in de novo patients (P , 0.05) than in those
irradiated, whereas IGF-I levels were significantly lower in
the operated and de novo patients than in the irradiated ones
(P , 0.005; Table 1). After 12 months of LAN treatment, GH
levels were significantly lower in de novo patients than in both
operated and irradiated patients (P , 0.05 and P , 0.0005,
respectively; Table 1). At this time point, operated patients
had significantly lower GH levels than those irradiated (P ,
0.005; Table 1). Similarly, IGF-I levels were significantly
lower in operated and de novo patients than in those irradi-
ated (P , 0.05, both; Table 1). After 24 months of LAN
treatment, GH levels were significantly lower in de novo
patients than in both operated and irradiated patients (P ,
0.05 and P , 0.005, respectively; Table 1). At this time point,
operated patients had significantly lower GH levels than
those irradiated (P , 0.005; Table 1), whereas no differences
were found in IGF-I levels.
On the basis of previous response to OCT therapy, patients
submitted to LAN therapy were analyzed as responders and
poor responders to OCT treatment. During long-term treat-
ment with LAN, only 37 of 63 acromegalics poorly respond-
ing to OCT treatment did not achieve GH suppression (59%),
whereas only 23 of 50 acromegalics poorly responding to
OCT did not normalize IGF-I levels (46%) (x2 5 12.54; P ,
0.0005 and x2 5 11.95; P , 0.0005, respectively).
Among the 23 de novo patients, significant tumor shrinkage
was documented by CT and/or MRI in 5 patients (22%) after
3 (n 5 2) and 6 (n 5 3) months of LAN treatment. In par-
ticular, 5 of 7 patients improved their visual field, and 3 of
3 patients improved headache. Among the 84 operated/
irradiated patients with documented tumor remnant at CT
and/or MRI, tumor shrinkage was observed in 5 patients
(5.9%), whereas no increase in tumor remnants was observed
in poorly responsive patients during LAN treatment.
Moreover, when patients were grouped into mA and MA,
significantly lower GH plasma levels were found in mA
patients basally and after 6 and 12 months of treatment (P ,
FIG. 2. Plasma IGF-I levels (mean 6 SEM) in the group of acromegalic
patients (n 5 118) before and during long-term treatment with LAN.
*, P , 0.0005 vs. basal.
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0.05), whereas significantly lower IGF-I plasma levels were
found in mA patients after 6, 12, and 24 months of treatment
(P , 0.05; data not shown).
During OCT treatment, abdominal discomfort after the
first injections was reported by 64 patients, and steatorrhea
was reported by 17 patients. These side effects disappeared
spontaneously in 26 patients and after treatment with pan-
creatic enzymes in some subjects. After the first injection of
LAN, abdominal discomfort was reported by 45 and steator-
rhea by 10 patients. Fifty of 118 patients reported moderated
discomfort at the injection site, lasting less than 24–48 h.
During LAN treatment period only 2 patients reported se-
rious side effects (worsening of headache, severe abdominal
pain, and steatorrhea) that forced them to withdraw from
treatment after 6 months. In all of the remaining 116 patients,
side effects were mild and spontaneously disappeared 1–4
days after the first injection, and specific treatment with
pancreatic enzymes was required only in 5 patients. Gall-
bladder ultrasonography was performed in all patients be-
fore and during the 24-month LAN treatment; gallstones
were detected in 4 patients, and sludge was found in 10
patients. Gallstones and sludge disappeared spontaneously
in 1 and 5 patients, respectively, and after ursodehoxicholic
acid treatment in the remaining 3 and 5 patients. No patient
developed signs of symptomatic colelithiasis or colecistitis.
Discussion
Acromegaly is a slow-developing disease featured by
chronic and progressive disability and, when left untreated,
increased mortality (1–16). Long-term treatment with sc OCT
has proven very effective in controlling GH/IGF-I hyperse-
cretion and has produced safe hormone levels in one third to
one half of patients in different series (28). However, the need
for multiple daily administrations produced compliance
problems in the majority of patients. The development of
new long-acting somatostatin analogs has overcome this in-
convenience (20–22, 25, 31–40). As LAN has become avail-
able only in recent years, few data have been reported on its
effectiveness in long-term treatment (22). In this study we
evaluated the effectiveness and tolerability of chronic treat-
ment with LAN in a large series of acromegalic patients. Our
results demonstrated that LAN induced a significant sup-
pression of circulating GH and IGF-I levels in the great ma-
jority of patients, allowing them to achieve disease control in
77% (GH) and 63% (IGF-I) of all 118 patients after 24 months
of therapy.
It is relevant to note that this study, in contrast with others,
included patients unselected with respect to a previous pos-
itive response to OCT treatment (33, 42).
Among the 95 patients previously treated with OCT, 63
(66%) did not achieve disease control during OCT treatment.
In contrast with the findings of another study (37), long-term
treatment with LAN seems to improve responsiveness in
patients poorly responsive to OCT. GH and IGF-I levels
during the 24-month LAN treatment period were signifi-
cantly lower (P , 0.005) in OCT-responsive than in OCT
poorly responsive patients, confirming the persistent pres-
ence of a group of somatostatin analog-resistant patients. It
is important to underline that all patients who responded to
OCT also responded to LAN treatment; furthermore, an ad-
ditional group of patients poorly responsive to OCT became
responsive to LAN. In the first study (37) addressing a similar
issue, the response to LAN treatment was evaluated during
a period of only 6 months. It is, therefore, likely that a longer
treatment period with the slow release formulations of so-
matostatin analogs can produce long-lasting suppression of
GH and IGF-I levels. On the basis of previous studies (21, 33),
all patients were admitted to LAN treatment at a dose of 30
mg every 14 days for the first 3 months. After this period, in
54 of 118 patients the frequency of LAN injection was in-
creased every 10 days, resulting in disease control in 17% of
patients. This indicates that the first modification of the fre-
quency of injection is better performed after 3 months of
treatment to achieve a cumulative effect of repeated injec-
tions (33, 43). In our group of 118 acromegalic patients, nor-
mal GH levels after 6, 12, and 24 months of treatment were
achieved in 31%, 56%, and 77% of patients, whereas normal
IGF-I levels were achieved in 30%, 47%, and 63% of patients,
respectively. Such a discrepancy could be explained either by
the presence of physiological fluctuations in GH levels or
by other IGF-I control factors that were not GH related
(22, 31, 35).
The prevalence of patients not achieving disease control
was significantly lower (P , 0.005) in de novo patients (22%)
than in those operated upon (36%) and irradiated (63%).
Shrinkage of GH-secreting adenomas has been reported in
about 30–50% of acromegalic patients treated with OCT (42,
44). In our series, tumor shrinkage could be documented in
5 of 23 de novo patients (22%). A similar percent shrinkage
rate was reported in a previous study of 22 patients with
acromegaly treated for 1–3 yr with LAN (22). Moreover, in
5 of 7 patients, visual field improved as a direct consequence
of tumor shrinkage; this points out that about one quarter of
de novo patients with pretreatment bitemporal hemianopsia
did not achieve adequate tumor shrinkage to relieve visual
compromise.
The better response observed in de novo patients compared
with operated and irradiated patients could be explained by
the possible presence of some modification caused by sur-
gery and radiotherapy, such as changes in vascular bed,
postsurgery fibrosis, alteration in the density of somatostatin
receptors, or wider GH fluctuations during previous OCT
therapy. On the other hand, we do not know whether the de
novo group contained a higher percentage of patients re-
sponsive to OCT therapy, potentially leading to a higher
success rate for this group.
The present study suggests that previous treatment with
radiotherapy induced partial resistance to somatostatin an-
alogs therapy, as shown by the presence of higher GH and
IGF-I levels throughout the 24-month period in the group of
irradiated patients; this aspect supports the better response
of de novo patients to LAN therapy. This is important infor-
mation, suggesting that radiotherapy may act as a negative
prognostic factor regarding the LAN response. This picture
strengthens the concept that previously operated or de novo
patients are characterized by a better outcome, in terms of
normal GH and IGF-I plasma levels, than patients previously
treated with radiotherapy.
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Controlled GH levels were achieved in 78% and 58% of
mA and MA patients, respectively (P , 0.05).
LAN was well tolerated during the entire study period in
all except two patients (1.7%) who withdrew from treatment
after 6 months due to the occurrence of severe side effects.
The more frequent side effects reported by patients were
represented by minor digestive problems such as nausea,
abdominal discomfort, and steatorrhea within the first 2–3
days after the injection. The presence of these side effects did
not induce any change in the frequency of LAN adminis-
tration. Moreover, the presence of abdominal discomfort and
steatorrhea was not related to the different regimen of LAN
administration. The prevalence and frequency of side effects
are superimposable to those reported in previous studies (21,
31, 33, 42).
In conclusion, this 24-month follow-up study demon-
strated that the somatostatin analog SR-lanreotide (30 mg)
was effective in controlling GH and IGF-I hypersecretion in
most acromegalic patients, especially in de novo patients.
Previous radiotherapy treatment seems to induce partial re-
sistance to LAN therapy. The higher prevalence of disease
control in de novo patients suggests that LAN can be an option
as first line therapy in such patients as well as a second line
treatment after unsuccessful surgery, as proposed for sc OCT
(44), and is accompanied by excellent patient compliance in
long-term treatments.
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